Current Role of Anti-Integrin Therapy in Inflammatory Bowel Disease

Authors

  • Kevin Winston Faculty of Medicine, Universitas Indonesia/Dr. Cipto Mangunkusumo General National Hospital, Jakarta
  • Hasan Maulahela Division of Gastroenterology, Department of Internal Medicine, Faculty of Medicine Universitas Indonesia/Dr. Cipto Mangukusumo General National Hospital, Jakarta
  • Lusiani Lusiani Division of Cardiology, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia/Dr. Cipto Mangunkusumo National General Hospital, Jakarta
  • Raditya Dewangga Faculty of Medicine, Universitas Indonesia/Dr. Cipto Mangunkusumo General National Hospital, Jakarta
  • Lazuardi G Ilhami Faculty of Medicine, Universitas Indonesia/Dr. Cipto Mangunkusumo General National Hospital, Jakarta

DOI:

https://doi.org/10.24871/2122020137-145

Keywords:

Anti-integrin, Inflammatory bowel disease (IBD), Crohn’s disease (CD), ulcerative colitis (UC) leukocyte trafficking, biological therapy

Abstract

Inflammatory bowel disease (IBD) is a chronic inflammatory intestinal disorder with multifactorial etiology. Management of IBD is divided into conventional treatment and new treatment with biologic agents. The first biologic agents used for IBD was tumor necrosis factor (TNF)-inhibitor. However, TNF-inhibitor as a biologic agent has several limitations such as low rate of clinical response and systemic immunosuppressive side effects. Anti-integrin is a recently developed biologic agent which selectively inhibits leukocyte trafficking towards site of inflammation. The inhibition is caused by blocking the actions of integrin, a cell adhesion molecules (CAMs) that is necessary for leukocyte trafficking and leukocytes express specific integrin receptors for specific organs. Therefore, use of gut-specific anti-integrin agents in IBD can selectively prevent influx of leukocytes into the intestine to reduce inflammation without reducing immune function in other locations. As a result, gut-specific anti-integrin is hypothesized to have lower risk of infections and lower risk of malignancy than TNF-inhibitor while maintaining high therapeutic benefits, making anti-integrin a promising therapy for IBD in the future.

Downloads

Published

2020-09-30

How to Cite

Winston, K., Maulahela, H., Lusiani, L., Dewangga, R., & Ilhami, L. G. (2020). Current Role of Anti-Integrin Therapy in Inflammatory Bowel Disease. The Indonesian Journal of Gastroenterology, Hepatology, and Digestive Endoscopy, 21(2), 137–145. https://doi.org/10.24871/2122020137-145

Issue

Vol. 21 No. 2 (2020): VOLUME 21, NUMBER 2, August 2020

Section

Review Article

License

Authors who publish with this journal agree to the following terms:

a. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

b. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.

c. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).